Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472380 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01472380 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 30 participants.
The verdict
NCT01472380, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects.
Interventions
- DRUG efavirenz
- DRUG fenofibric acid 105 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01472380
The ClinicalTrials.gov registry entry for NCT01472380 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which efavirenz is the first listed.
NCT01472380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01472380 about?
NCT01472380 is a clinical study titled "A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz". Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects.
What is the current status of trial NCT01472380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01472380?
The interventions under investigation include: efavirenz (DRUG), fenofibric acid 105 mg (DRUG).
Who is sponsoring clinical trial NCT01472380?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.